ArticleMolecular medicine reports2026
Therapeutic effects of exosome‑based hyperin delivery in a cyclophosphamide‑induced mouse model of diminished ovarian reserve.
Article in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of more effective and affordable strategies for the treatment of diminished ovarian reserve (DOR) is of notable importance due to its increasing prevalence in young patients and the limited efficacy of current clinical interventions in restoring fertility. The present study investigated the efficacy of umbilical cord‑derived mesenchymal stem cell (UCMSC)‑derived exosome‑based hyperin delivery in ameliorating cyclophosphamide (CP)‑induced DOR in mice, and elucidated the potential underlying mechanisms of resulting therapeutic benefits. Exosomes were isolated from UCMSCs and encapsulated with hyperin using ultrasonication. The DOR mouse model itself was established via treatment with CP; these model mice were then treated with hyperin, UCMSC‑exosome controls or hyperin‑encapsulated UCMSC‑exosomes. After treatment, body weight, estrous cycles and general health were monitored. Ovarian tissues were evaluated histologically, and serum levels of anti‑Müllerian hormone, follicle‑stimulating hormone and estradiol were measured via enzyme‑linked immunosorbent assay. Ovarian expression of the autophagy markers LC3 II, Beclin‑1 and P62 was analyzed via western blotting. CP treatment led to a notable deterioration in general health, body weight and ovarian function, as evidenced by altered estrous cycles and reduced follicle counts. Treatment with hyperin‑loaded UCMSC‑exosomes resulted in improvements in body weight, the restoration of estrous cycles. Notably, compared with the model group, mice treated with hyperin‑loaded UCMSC‑exosomes demonstrated increased primordial follicle counts and decreased atretic follicle counts. Treatment with hyperin‑loaded UCMSC‑exosomes modulated autophagic activity within the ovaries, with reduced LC3‑Ⅱ and beclin‑1 levels and increased P62 levels following treatment with hyperin‑loaded UCMSC‑derived exosomes. UCMSC‑derived exosomes loaded with hyperin effectively mitigated the adverse effects of CP on ovarian function, potentially via the modulation of autophagic processes. These findings supported the therapeutic potential of engineered exosomes for treating DOR, highlighting a novel approach for fertility preservation and reproductive medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.